
Evogene quarterly loss widens to $2.86 million
Pontos principais
- Evogene (NASDAQ:EVGN) reported a third-quarter 2026 net loss of US$2.862 million, compared with net income of US$5.197 million a year earlier.
- Quarterly revenue fell to US$141,000 from US$312,000, while nine-month revenue declined to US$822,000 from US$3.189 million.
- The company advanced two internal development programmes targeting acute graft-versus-host disease and fungicide-resistant Septoria, with selected agricultural compounds reducing disease severity by up to 75% in plant tissue tests.
Evogene (NASDAQ:EVGN) reported a third-quarter 2026 net loss of US$2.862 million, compared with net income of US$5.197 million in the same period last year, as revenue declined.
Quarterly revenue fell to US$141,000 from US$312,000 following the termination of its Bayer collaboration in May 2026, while nine-month revenue declined to US$822,000 from US$3.189 million, mainly because of lower seed sales at its Casterra subsidiary.
Operating loss widened to US$2.982 million from US$2.427 million in the third quarter, while the nine-month net loss increased to US$10.525 million from US$2.473 million and cash holdings reached approximately US$9.2 million at September 30.
Meanwhile, the company reported approximately US$2.4 million in cash usage during the third quarter.
Eslewhere, Evogene is refining internally developed small-molecule drug candidates targeting acute graft-versus-host disease, with early testing showing nanomolar biological potency and preliminary absorption, distribution, metabolism and excretion (ADME) and toxicology profiles ahead of planned IND-enabling studies.
Its AgPlenus subsidiary identified compounds active against fungicide-resistant Septoria strains, with selected molecules reducing disease severity by up to 75% in plant tissue tests and showing activity against additional fungal pathogens.




